CD26 Is a Potential Therapeutic Target by Humanized Monoclonal Antibody for the Treatment of Multiple Myeloma

Blood Cancer Journal - United States
doi 10.1038/s41408-018-0127-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

FOXM1 Is a Therapeutic Target in High-Risk Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Therapeutic Targeting of N-Cadherin Is an Effective Treatment for Multiple Myeloma

British Journal of Haematology
Hematology
2015English

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

EZH2 as a Therapeutic Target for Multiple Myeloma and Other Haematological Malignancies

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

The Therapeutic Potential of Cell Cycle Targeting in Multiple Myeloma

Oncotarget
Oncology
2017English

The Therapeutic Monoclonal Antibody Market

mAbs
AllergyImmunology
2015English

Current Use of Monoclonal Antibodies in the Treatment of Multiple Myeloma

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy